Nov 29, 2022 / 01:30PM GMT
Guyn Kim - Piper Sandler & Co., Research Division - Senior Research Analyst
Good morning. Thank you all for joining us for the 34th Annual Piper Sandler Healthcare Conference. My name is Do Kim. I'm one of the Biotech Analysts here at Piper. For our next company presentation, we have Exelixis. And it's my pleasure to welcome Andrew Peters, Senior Vice President and Head of Strategy at Exelixis.
Questions and Answers:
Guyn Kim - Piper Sandler & Co., Research Division - Senior Research AnalystAndrew, maybe we could start in your area of expertise and talk about the number of collaborations, licensing deals that were done recently, primarily for assets in the early stages. Maybe you could expand on how you think about the strategic decision to go after early stage assets versus mid to late stage or a straight-out acquisition with your cash balance?
Andrew Ross Peters - Exelixis, Inc. - SVP of Strategy
Yes. So happy to get into that, and thank you for having us and presenting at the conference.
Trustpilot
